Individual research recommendation details

Recommendation ID

NG191/19

Question

What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?

Any explanatory notes
(if applicable)

Suggested PICO (Population, Intervention, Comparator, Outcome)

P: people with COVID-19, particularly groups for which current evidence is lacking, for example:

• in pregnancy and breastfeeding
• people 65 years and over
• children and young people under 18
• people from minority ethnic family backgrounds
• people with risk factors for severe COVID-19

I: vitamin D (800 IU/day or less and more than 800 IU/day; single or multiple doses)

C:

• standard care
• placebo

O: effectiveness outcomes:

• all-cause hospitalisation
• all-cause mortality
• need for mechanical ventilation
• need for non-invasive respiratory support
• admission to intensive care
• symptom alleviation
• adherence to therapy
• long-term effects of COVID-19 (at least 4 weeks from acute COVID-19 onset)

Safety outcomes:

• any adverse event
• adverse event leading to trial discontinuation
• serious adverse events

Source guidance details

Comes from guidance

COVID-19 rapid guideline: managing COVID-19

Number

NG191

Date issued

March 2021

Other details